MedTrace Logo

Relationship Between RAR and MACEs in AMI-CS Patients During Hospitalization

NCT07507110 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 264

Last updated 2026-04-02

No results posted yet for this study

Summary

This is a retrospective study from double center: Xuzhou Central Hospital and The First People's Hospital of Yancheng. Acute myocardial infarction (AMI) were screened and AMI complicating with cardiogenic shock were included. This study is to investigate the relationship between red blood cell distribution width-to-albumin ratio (RAR) and major adverse cardiovascular events (MACEs) in acute myocardial infarction complicated with cardiogenic shock (AMI-CS) patients during hospitalization.

Conditions

Interventions

DIAGNOSTIC_TEST

Includ the inclusion/exclusion criteria of AMI-CS

he inclusion criteria were as follows: (1) Age over 18 years and under 90 years; (2) Meeting the diagnostic criteria for acute myocardial infarction\[16\]: myocardial injury markers (preferably troponin) ≥ 99th percentile of the upper limit of normal value, combined with at least one evidence of myocardial ischemia: persistent myocardial ischemic symptoms ≥ 30 minutes; accompanied by ST-segment elevation or depression on electrocardiogram; (3) Meeting the diagnostic criteria for cardiogenic shock\[17\]: systolic blood pressure \< 90 mmHg, accompanied by clinical symptoms of pulmonary congestion such as dyspnea, and at least one of the following peripheral organ perfusion impairments: altered mental status; cold and clammy skin; urine output \< 30 ml/h; or serum lactate level \> 2.0 mmol/L. The exclusion criteria included: (1) Coexisting cerebrovascular disease, peripheral vascular disease or embolic disease; (2) Myocardial infarction caused by coronary artery embolism or blood flow interrupti

Sponsors & Collaborators

  • Xuzhou Central Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-01
Primary Completion
2024-10-31
Completion
2025-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07507110 on ClinicalTrials.gov